Deptor: Not only a mTOR inhibitor

Journal of Experimental and Clinical Cancer Research

Volumn 36, Issue 1, 2017, Pages

  Catena, Valeria ^a   Fanciulli, Maurizio ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer; Cancer therapy; Deptor; ER homeostasis; mTOR

Indexed keywords

DEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; UNCLASSIFIED DRUG; DEPTOR PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; DRUG TARGETING; HUMAN; INFLAMMATION; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; ANTIBODY SPECIFICITY; ENDOPLASMIC RETICULUM STRESS; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; AUTOPHAGY; CELL PROLIFERATION; ENDOPLASMIC RETICULUM STRESS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 85009476796     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-016-0484-y     Document Type: Review

References (51)

1. Wang Z, Zhong J, Inuzuka H, Gao D, Shaik S, Sarkar FH, et al. An evolving role for DEPTOR in tumor development and progression. Neoplasia. 2012;14(5):368-75.
2. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873-86. doi: 10.1016/j.cell.2009.03.046.
3. Panic N, Larghi A, Amore R, Pastorino R, Bulajic M, Costamagna G, et al. Single nucleotide polymorphisms within the 8Q24 region are not associated with the risk of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointestin Liver Dis. 2016;25(3):311-5. doi: 10.15403/jgld.2014.1121.253.q24.
4. Chen S, Hamm HE. DEP domains: more than just membrane anchors. Dev Cell. 2006;11(4):436-8. doi: 10.1016/j.devcel.2006.09.011.
5. Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 2011;44(2):304-16. doi: 10.1016/j.molcel.2011.08.029.
6. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004;36(1):40-5. doi: 10.1038/ng1285.
7. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101(16):6062-7. doi: 10.1073/pnas.0400782101.
8. Catena V, Bruno T, De Nicola F, Goeman F, Pallocca M, Iezzi S, et al. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells. Oncotarget. 2016. doi: 10.18632/oncotarget.12060.
9. Liu NB, Zhang JH, Liu YF, Li J, Zhang ZZ, Li JW, et al. High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma. OncoTargets Ther. 2015;8:3449-55. doi: 10.2147/OTT.S92862.
10. Li H, Sun GY, Zhao Y, Thomas D, Greenson JK, Zalupski MM, et al. DEPTOR has growth suppression activity against pancreatic cancer cells. Oncotarget. 2014;5(24):12811-9. doi: 10.18632/oncotarget.2659.
11. Zhou X, Guo J, Ji Y, Pan G, Liu T, Zhu H, et al. Reciprocal negative regulation between EGFR and DEPTOR plays an important role in the progression of lung adenocarcinoma. Mol Cancer Res. 2016;14(5):448-57. doi: 10.1158/1541-7786.MCR-15-0480.
12. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol. 2012;4(2). doi: 10.1101/cshperspect.a011593.
13. Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2016. doi: 10.1038/onc.2016.363.
14. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-93. doi: 10.1016/j.cell.2012.03.017.
15. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21-35. doi: 10.1038/nrm3025.
16. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501. doi: 10.1038/nrc839.
17. Zhang H, Chen J, Zeng Z, Que W, Zhou L. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. Int J Mol Med. 2013;31(5):1127-34. doi: 10.3892/ijmm.2013.1299.
18. Kazi AA, Hong-Brown L, Lang SM, Lang CH. Deptor knockdown enhances mTOR Activity and protein synthesis in myocytes and ameliorates disuse muscle atrophy. Mol Med. 2011;17(9-10):925-36. doi: 10.2119/molmed.2011.00070.
19. Agrawal P, Reynolds J, Chew S, Lamba DA, Hughes RE. DEPTOR is a stemness factor that regulates pluripotency of embryonic stem cells. J Biol Chem. 2014;289(46):31818-26. doi: 10.1074/jbc.M114.565838.
20. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3-12. doi: 10.1002/path.2697.
21. Eskelinen EL. The dual role of autophagy in cancer. Curr Opin Pharmacol. 2011;11(4):294-300. doi: 10.1016/j.coph.2011.03.009.
22. Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, et al. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell. 2011;44(2):290-303. doi: 10.1016/j.molcel.2011.08.030.
23. Lee MN, Ha SH, Kim J, Koh A, Lee CS, Kim JH, et al. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol. 2009;29(14):3991-4001. doi: 10.1128/MCB.00165-09.
24. Antonioli M, Albiero F, Nazio F, Vescovo T, Perdomo AB, Corazzari M, et al. AMBRA1 interplay with cullin E3 ubiquitin ligases regulates autophagy dynamics. Dev Cell. 2014;31(6):734-46. doi: 10.1016/j.devcel.2014.11.013.
25. Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, et al. Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J. 2015;34(9):1214-30. doi: 10.15252/embj.201489920.
26. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465(7300):942-6. doi: 10.1038/nature09076.
27. Davies J, Zachariades E, Rogers-Broadway KR, Karteris E. Elucidating the role of DEPTOR in Alzheimer's disease. Int J Mol Med. 2014;34(5):1195-200. doi: 10.3892/ijmm.2014.1895.
28. Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 2013;122(10):1833-42. doi: 10.1182/blood-2013-03-488486.
29. Meng ZX, Wang L, Xiao Y, Lin JD. The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity. Diabetes. 2014;63(5):1533-45. doi: 10.2337/db13-1061.
30. Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-16. doi: 10.1182/blood-2005-08-3531.
31. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-42. doi: 10.1158/1535-7163.MCT-11-0433.
32. Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, et al. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol Cell. 2011;44(2):317-24. doi: 10.1016/j.molcel.2011.09.005.
33. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399-434. doi: 10.1146/annurev.biochem.78.101807.093809.
34. Yoon MS, Rosenberger CL, Wu C, Truong N, Sweedler JV, Chen J. Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid. Mol Cell. 2015;58(3):549-56. doi: 10.1016/j.molcel.2015.03.028.
35. Iezzi S, Fanciulli M. Discovering Che-1/AATF: a new attractive target for cancer therapy. Front Genet. 2015;6:141. doi: 10.3389/fgene.2015.00141.
36. Bruno T, De Nicola F, Iezzi S, Lecis D, D'Angelo C, Di Padova M, et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell. 2006;10(6):473-86. doi: 10.1016/j.ccr.2006.10.012.
37. Hu Y, Su H, Liu C, Wang Z, Huang L, Wang Q, et al. DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia. Oncogene. 2016. doi: 10.1038/onc.2016.275.
38. Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M, et al. DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. Biochem Biophys Res Commun. 2015;460(4):1047-52. doi: 10.1016/j.bbrc.2015.03.148.
39. Lai EY, Chen ZG, Zhou X, Fan XR, Wang H, Lai PL, et al. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer. Asian Pac J Cancer Prev. 2014;15(11):4589-94.
40. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014;111(1):409-14. doi: 10.1073/pnas.1314469111.
41. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008;30(6):701-11. doi: 10.1016/j.molcel.2008.04.027.
42. Proud CG. Dynamic balancing: DEPTOR tips the scales. J Mol Cell Biol. 2009;1(2):61-3. doi: 10.1093/jmcb/mjp012.
43. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007.
44. Srinivas KP, Viji R, Dan VM, Sajitha IS, Prakash R, Rahul PV, et al. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. Oncotarget. 2016;7(17):24154-71. doi: 10.18632/oncotarget.8131.
45. Pei L, Xie P, Zhou E, Yang Q, Luo Y, Tang Z. Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma. Mol Med Rep. 2011;4(5):817-23. doi: 10.3892/mmr.2011.503.
46. Parvani JG, Davuluri G, Wendt MK, Espinosa C, Tian M, Danielpour D, et al. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia. 2015;17(3):317-28. doi: 10.1016/j.neo.2015.02.003.
47. Zhang HR, Chen JM, Zeng ZY, Que WZ. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res. 2013;41(3):584-95. doi: 10.1177/0300060513480920.
48. Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk lymphoma. 2010;51(11):2126-9. doi: 10.3109/10428194.2010.509893.
49. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, et al. Cytotoxic properties of a DEPTOR-mTOR inhibitor in multiple myeloma cells. Cancer Res. 2016. doi: 10.1158/0008-5472.CAN-16-1019.
50. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, et al. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014;5(11-12):407-19. doi: 10.18632/genesandcancer.44.
51. Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, De Stefano V, et al. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res. 2012;31:17. doi: 10.1186/1756-9966-31-17.